Brilique® ticagrelor

Brilique (ticagrelor) is een orale plaatjesaggregatieremmer voor de behandeling van acuut coronair syndroom (ACS) in een chemische klasse genaamd cyclopentyltriazolopyrimidines (CPTP's). Het is de eerste reversibel bindende, orale adenosinedifosfaat (ADP) receptorantagonist. Brilique is de enige P2Y12-blokker die goedgekeurd is voor bescherming van patiënten tegen herhaalde CV-voorvallen* in zowel de setting van acute als de langetermijnbehandeling.1,4,5

*Het samengestelde primaire eindpunt van de PLATO (1 jaar) en PEGASUS (maximaal 3 jaar) studies was het eerste optreden van CV-overlijden, MI of beroerte2,3

Referenties

  1. Brilique, Samenvatting van de productkenmerken, meest recente versie
  2. Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791-1800.
  3. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057.
  4. Eli Lilly. Samenvatting van de productkenmerken voor prasugrel. 2016.
  5. Sanofi. Samenvatting van de productkenmerken voor Plavix. 2016.
  6. Levine. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2016.
  7. Fox KA, Carruthers KF, Dunbar DR, et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J. 2010;31(22):2755-2764.
  8. Fox KA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333(7578):1091.
  9. Carlson G et al. Poster gepresenteerd tijdens de 63e jaarlijkse wetenschappelijke sessie van het American College of Cardiology, Washington DC, VS, maart 2014. 2014.
  10. Teng. CRUSHING TICAGRELOR TABLETS ACCELERATES EXPOSURE COMPARED WITH INTACT TABLETS. 2014.
  11. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304(12):1350-1357.
  12. Cutlip DE, Chhabra AG, Baim DS, et al. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation. 2004;110(10):1226-1230.
  13. Farkouh ME, Mathew V. The PROSPECT of changing our approach to acute coronary syndromes. JACC Cardiovasc Imaging. 2012;5(3 Suppl):S73-S75.
  14. Gruppetta M, Calleja N, Fava S. Long-term survival after acute myocardial infarction and relation to type 2 diabetes and other risk factors. Clin Cardiol. 2010;33(7):424-429.
  15. Husted S, James S, Becker RC, et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes. 2012;5(5):680-688.
  16. Koek HL, Soedamah-Muthu SS, Kardaun JW, et al. Short- and long-term mortality after acute myocardial infarction: comparison of patients with and without diabetes mellitus. Eur J Epidemiol. 2007;22(12):883-888.
  17. Nakatani D, Sakata Y, Suna S, et al. Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction. Circ J. 2013;77(2):439-446.
  18. Parodi G, Storey RF. Dyspnoea management in acute coronary syndrome patients treated with ticagrelor. Eur Heart J Acute Cardiovasc Care. 2015;4(6):555-560.
  19. Magnani G, Storey RF, Steg G, et al. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. Eur Heart J. 2016;37(4):400-408.
  20. Bonaca. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. 2014.
  21. Bonaca et al. Eur Heart J 2016; 37:1133-1142
  22. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36(19):1163-1170.
  23. Janzon M et al. JACC 2015: Poster: In Press
  24. Stone GW et al. N Eng J Med 2012; 364:326-335
  25. Bonaca MP et al. Efficacy of long-term Ticagrelor in patients with coronary stents in PEGASUS-TIMI 54. Presented at Transcatheter Cardiovascular Therapeutics, 2015
  26. Bonaca et al. Am Heart J 2014;167:437-444
  27. Kovanen et al. Heart Metab 2007;36:9-14
  28. Roffe et al. Eur Heart J 2015;epub ahead of print 
  29. Steg et al. Eur Heart J 2012;33:2569-2619
  30. Roffi M. Coronary revascularization in diabetic patients. Eur Heart J. 2015;36(24):1496.

NS ID BE-1337-RD09/2017-WEB